• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis of metabolic reprogramming induced by cellular environment and its application to control hepato-carcinogenesis

Research Project

Project/Area Number 18H02798
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionKumamoto University

Principal Investigator

SASAKI YUTAKA  熊本大学, 大学院生命科学研究部(医), 名誉教授 (70235282)

Co-Investigator(Kenkyū-buntansha) 長岡 克弥  熊本大学, 病院, 助教 (00759524)
渡邊 丈久  熊本大学, 大学院生命科学研究部(医), 助教 (20634843)
直江 秀昭  熊本大学, 病院, 講師 (30599246)
荒木 令江  熊本大学, 大学院生命科学研究部(医), 准教授 (80253722)
藤元 治朗  兵庫医科大学, 医学部, 特別招聘教授 (90199373)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2019: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Keywords肝癌 / 細胞環境 / 代謝リプログラミング / 治療抵抗性 / 分子標的治療薬 / 効果予測マーカー / エピジェネテイクス / オミクス解析 / 原発性肝癌 / マルチオミクス解析 / ヒストン脱メチル化酵素 / 転写因子 / メタボローム解析 / 肝発癌 / メタボローム / メダボローム解析
Outline of Final Research Achievements

When gene expression in response to Sorafenib (SFN), a molecular target agent for HCCs, was compared between HepG2 cells and HepG2- SFN resistant cells (HepG2-SR), genes in the metabolism of lipids were significantly enriched in both cell lines, whereas gene expressions by SREBP1C were significantly enhanced in HepG2-SR cells. Clusterin (CLU), one of the target genes of SREBP1C, was up-regulated in HepG2-SR cells and knock-down with siRNA enhanced SFN treatment response, suggesting that CLU might play a role in SFN resistance. In addition, an increase in serum CLU level one month after SFN treatment initiation was significantly associated with shorter PFS in the HCC patients, indicating that serum CLU might be a potential biomarker for early prediction of SFN response. On the other hand, hypoxia or high fat microenvironment enhanced expression of LSD1 and LSD2, histone demethylase, in hepatoma cell lines, leading to lipid and carbohydrate reprogramming required for cancer cell growth.

Academic Significance and Societal Importance of the Research Achievements

低酸素環境、分子標的治療薬存在下などの細胞環境に肝癌細胞は適応し、代謝リプログラミングとして細胞内の代謝を変化させ、さらに治療抵抗性を獲得して増殖進展を続ける。そこで本研究では、さまざまな細胞環境下で誘導されるエピゲノム制御分子(遺伝子発現を調節する分子)とそれによりもたらされる代謝変化を明らかにしたことで、代謝リプログラミングの制御を介した新たな治療法に発展することが期待される。さらに分子標的治療薬が代謝リプログラミングを介して誘導する治療抵抗性分子を同定し、治療効果の早期予測血清マーカーとしての有用性を証明したため、今後、肝癌の治療法選択に応用される可能性がある。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Annual Research Report
  • 2018 Annual Research Report
  • Research Products

    (40 results)

All 2021 2020 2019 2018

All Journal Article (17 results) (of which Int'l Joint Research: 8 results,  Peer Reviewed: 17 results,  Open Access: 17 results) Presentation (21 results) (of which Int'l Joint Research: 6 results) Book (2 results)

  • [Journal Article] Modified albumin?bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients2021

    • Author(s)
      Tokunaga Takayuki、Tanaka Motohiko、Tanaka Kentaro、Narahara Satoshi、Kawasaki Takeshi、Yoshimaru Yoko、Nagaoka Katsuya、Watanabe Takehisa、Tateyama Masakuni、Naoe Hideaki、Sasaki Yutaka、Tanaka Yasuhito
    • Journal Title

      International Journal of Clinical Oncology

      Volume: 26 Issue: 5 Pages: 922-932

    • DOI

      10.1007/s10147-020-01835-2

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Ten‐Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild‐Type Isocitrate Dehydrogenase 12021

    • Author(s)
      Bai Xuewei、Zhang Hongyu、Zhou Yamei、Nagaoka Katsuya、Meng Jialin、Ji Chengcheng、Liu Dan、Dong Xianghui、Cao Kevin、Mulla Joud、Cheng Zhixiang、Mueller William、Bay Amalia、Hildebrand Grace、Lu Shaolei、Wallace Joselynn、Wands Jack R.、Sun Bei、Huang Chiung‐Kuei
    • Journal Title

      Hepatology

      Volume: 73 Issue: 5 Pages: 1747-1763

    • DOI

      10.1002/hep.31486

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Murine neonatal ketogenesis preserves mitochondrial energetics by preventing protein hyperacetylation2021

    • Author(s)
      Arima Yuichiro、Nakagawa Yoshiko、Takeo Toru、Ishida Toshifumi、Yamada Toshihiro、et al.
    • Journal Title

      Nature Metabolism

      Volume: 3 Issue: 2 Pages: 196-210

    • DOI

      10.1038/s42255-021-00342-6

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Endoscopic and clinicopathological features of superficial Barrett's esophageal adenocarcinoma - With special reference to difference derived from Short-segment versus Long-segment Barrett’s esophagus2020

    • Author(s)
      Yamasaki A, Sasaki Y, Fujisaki J, et al.
    • Journal Title

      J Gastro Hepatol

      Volume: 35 Issue: 2 Pages: 211-217

    • DOI

      10.1111/jgh.14827

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Prostaglandin E2-EP4 axis promotes lipolysis and fibrosis in adipose tissue leading to ectopic fat deposition and insulin resistance.2020

    • Author(s)
      Inazumi T, Yamada K, Shirata N, Sato H, Taketomi Y, Morita K, Hohjoh H, Tsuchiya S, Oniki K, Watanabe T, Sasaki Y, Oike Y, Ogata Y, Saruwatari J, Murakami M, Sugimoto Y.
    • Journal Title

      Cell Rep.

      Volume: 33 Issue: 2 Pages: 108265-108265

    • DOI

      10.1016/j.celrep.2020.108265

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study2020

    • Author(s)
      Tateyama Masakuni、Naoe Hideaki、Tanaka Motohiko、Tanaka Kentaro、Narahara Satoshi、Tokunaga Takayuki、Kawasaki Takeshi、Yoshimaru Yoko、Nagaoka Katsuya、Watanabe Takehisa、Setoyama Hiroko、Sasaki Yutaka、Tanaka Yasuhito
    • Journal Title

      BMC Gastroenterology

      Volume: 20 Issue: 1 Pages: 371-371

    • DOI

      10.1186/s12876-020-01501-x

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The metabolite, alpha-ketoglutarate inhibits non-alcoholic fatty liver disease progression by targeting lipid metabolism2020

    • Author(s)
      Nagaoka K. Mulla J, Huang, CK, et al.
    • Journal Title

      Liver Research

      Volume: 4 Pages: 94-100

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis2020

    • Author(s)
      Nagaoka Katsuya、Ogawa Kousuke、Ji Chengcheng、Cao Kevin Y.、Bai Xuewei、Mulla Joud、Cheng Zhixiang、Wands Jack R.、Huang Chiung-Kuei
    • Journal Title

      Digestive Diseases and Sciences

      Volume: 66 Issue: 4 Pages: 1080-1089

    • DOI

      10.1007/s10620-020-06330-2

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Risk stratification of advanced colorectal neoplasia after baseline colonoscopy: Cohort study of 17 Japanese community practices2019

    • Author(s)
      Shono Takashi、Oyama Shinichiro、Oda Yasushi、Yokomine Kazunori、Murakami Yoshitaka、Miyamoto Hideaki、Tanaka Motohiko、Naoe Hideaki、Sasaki Yutaka、the Kumamoto Colon Cancer Study Group
    • Journal Title

      Digestive Endoscopy

      Volume: 32 Issue: 1 Pages: 106-113

    • DOI

      10.1111/den.13516

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial2019

    • Author(s)
      Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y
    • Journal Title

      Liver Cancer

      Volume: 8 Issue: 6 Pages: 505

    • DOI

      10.1159/000503032

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update2019

    • Author(s)
      Ryosuke Tateishi, Yutaka Sasaki, Kazuhiko Koike et al.
    • Journal Title

      Journal of Gastroenterology

      Volume: 54 Pages: 367-376

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.2019

    • Author(s)
      Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T
    • Journal Title

      Cancer Med.

      Volume: 印刷中 Issue: 5 Pages: 2646-2653

    • DOI

      10.1002/cam4.2061

    • Related Report
      2019 Annual Research Report 2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study2019

    • Author(s)
      Tatsuya Ide, Hironori Koga, Yutaka Sasaki, Takuji Torimura et al.
    • Journal Title

      Hepatology International

      Volume: 13 Pages: 293-301

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study2019

    • Author(s)
      Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miuma S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, Torimura T
    • Journal Title

      Hepatol Int.

      Volume: 印刷中 Issue: 3 Pages: 293-301

    • DOI

      10.1007/s12072-019-09939-2

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.2019

    • Author(s)
      Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.
    • Journal Title

      J Gastroenterol.

      Volume: 54 Issue: 4 Pages: 367-376

    • DOI

      10.1007/s00535-018-1532-5

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Genetic Fusion of Type-I Interferon to a Recombinant Albumin Mutant with polymannosylated N-linked oligosaccharide attached is a Novel and Superior Kupffer Cell Targeting Agent for the Treatment of Hepatitis.2018

    • Author(s)
      Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T.
    • Journal Title

      Drug Delivery

      Volume: 25 Issue: 1 Pages: 1067-1077

    • DOI

      10.1080/10717544.2018.1464083

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial2018

    • Author(s)
      Kudo M、Ueshima K、Yokosuka O、Ogasawara S、Obi S、Izumi N、Aikata H、Nagano H、Hatano E、Sasaki Y、Hino K、Kumada T、Yamamoto K、Imai Y、Iwadou S、Ogawa C、Okusaka T、Kanai F、Akazawa K、Yoshimura K、Johnson P、Arai Y
    • Journal Title

      The Lancet Gastroenterology & Hepatology

      Volume: 3 Issue: 6 Pages: 424-432

    • DOI

      10.1016/s2468-1253(18)30078-5

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] A novel serum biomarker, Clusterin, and related predictive index scoring could be an early predictor of response to Sorafenib in patients with advanced hepatocellular carcinoma2020

    • Author(s)
      Narahara S, Watanabe T, Nagaoka K, Naoe H, Sasaki Y, Tanaka Y, et al.
    • Organizer
      Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
    • Related Report
      2020 Annual Research Report
  • [Presentation] Prognostic factors associated with survival in hepatocellular carcinoma patients progressed on lenvatinib therapy, premising subsequent chemotherapy2020

    • Author(s)
      Tokunaga T, Nagaoka K, Watanabe T, Tanaka Y, et al.
    • Organizer
      Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
    • Related Report
      2020 Annual Research Report
  • [Presentation] 当院におけるHBV電子カルテスクリーニングシステム導入の有用性の評価2020

    • Author(s)
      渡邊丈久、楢原哲史、田中健太郎、徳永尭之、川崎剛、吉丸洋子、長岡克弥、瀬戸山博子、立山雅邦、田中基彦
    • Organizer
      第24回日本肝臓学会大会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 当院における高齢者に対する胃ESDの安全性、予後、術後栄養状態の検討2020

    • Author(s)
      小山真一郎、馬場秀夫、佐々木裕
    • Organizer
      第62回日本消化器病学会大会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 翻訳後修飾の網羅的解析による肝癌の治療抵抗性の解明2020

    • Author(s)
      直江秀昭、渡邊丈久、田中基彦
    • Organizer
      第56回日本肝臓学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] DAAs治療後の血清Exosome中miRNAの変化はSVR後の生体反応を反映する2020

    • Author(s)
      渡邊丈久
    • Organizer
      第56回日本肝臓学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] C型慢性肝疾患,初発肝癌における高齢者に対する治療後の現状2020

    • Author(s)
      立山雅邦、田中基彦、佐々木裕
    • Organizer
      第106回日本消化器病学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 肝炎ウイルス陽性患者の受診勧奨を目的とした肝臓非専門医療機関との診療連携システムの構築2020

    • Author(s)
      瀬戸山博子、田中基彦、佐々木裕
    • Organizer
      第106回日本消化器病学会総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] MULTI-OMICS ANALYSES IDENTIFY NUCLEOPHOSMIN AS A KEY REGULATOR OF APOPTOSIS RESISTANCE IN HUMAN HEPATOCELLULAR CARCINOMA2019

    • Author(s)
      Hideaki Naoe, Takehisa Watanabe, Katsuya Nagaoka, Nahoko Fujimoto, Norie Araki, Jiro Fujimoto, Motohiko Tanaka and Yutaka Sasaki
    • Organizer
      The Liver Meeting 2019 - AASLD
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] OPTIMAL STRATEGY OF SWITCHING FROM TRANSARTERIAL CHEMOEMBOLIZATION TO MOLECULAR TARGETED THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA2019

    • Author(s)
      Takayuki Tokunaga, Motohiko Tanaka, Kentaro Tanaka, Satoshi Narahara, Yoko Yoshimaru, Tekeshi Kawasaki, Katsuya Nagaoka, Takehisa Watanabe, Masakuni Tateyama and Yutaka Sasaki
    • Organizer
      The Liver Meeting 2019 - AASLD
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] UPREGULATION OF SECRETORY CLUSTERIN IN RESPONSE TO SORAFENIB LINKS TO ACQUIRED TREATMENT RESISTANCE OF HEPATOCELLULAR CARCINOMA.2019

    • Author(s)
      Satoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka, Nahoko Fujimoto, Kentaro Tanaka, Takeshi Kawasaki, Yoko Yoshimaru, Masakuni Tateyama, Hideaki Naoe, Motohiko Tanaka and Yutaka Sasaki
    • Organizer
      The Liver Meeting 2019 - AASLD
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] C型慢性肝疾患,初発肝癌における高齢者に対する治療後の現状2019

    • Author(s)
      立山雅邦、田中基彦、佐々木裕
    • Organizer
      第105回日本消化器病学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 切除不能進行肝細胞癌に対するソラフェニブを基軸とした集学的治療戦略2019

    • Author(s)
      徳永尭之、田中健太郎、楢原哲史、長岡克弥、吉丸洋子、渡邊丈久、立山雅邦、田中基彦、佐々木裕
    • Organizer
      第105回日本消化器病学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 肝細胞癌に対するソラフェニブの治療効果を早期に予測する新規血清バイオマーカーの解析2019

    • Author(s)
      楢原哲史、渡邊丈久、長岡克弥、田中健太郎、徳永尭之、川崎剛、吉丸洋子、瀬戸山博子、立山雅邦、直江秀昭、田中基彦、佐々木裕
    • Organizer
      第55回日本肝臓学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 肝細胞癌に対する肝動脈化学塞栓術から分子標的治療への適切な切り替えタイミングの検討2019

    • Author(s)
      徳永尭之、田中健太郎、楢原哲史、吉丸洋子、川崎剛、長岡克弥、渡邊丈久、立山雅邦、田中基彦、佐々木裕
    • Organizer
      第55回日本肝臓学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 進行肝細胞癌に対する集学的なソラフェニブ治療戦略2019

    • Author(s)
      28.徳永尭之、田中基彦、田中健太郎、楢原哲史、吉丸洋子、川崎剛、長岡克弥、渡邊丈久、立山雅邦、佐々木裕
    • Organizer
      JDDW 2019(第27回 日本消化器関連学会週間)
    • Related Report
      2019 Annual Research Report
  • [Presentation] Prognostic Factors in Patients with Advanced HCC Receiving Sorafenib or Hepatic Arterial Infusion Chemotherapy2018

    • Author(s)
      Motohiko Tanaka, Takayuki Tokunaga, Kentaro Tanaka, Satoshi Narahara, Takeshi Kawasaki, Yoko Yoshimaru, Takehisa Watanabe, Masakuni Tateyama, Hideaki Naoe, Yutaka Sasaki
    • Organizer
      The Asian Pacific Association for the Study of the Liver
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Treatment Strategy Based on Sorafenib for Advanced Hepatocellular Carcinoma2018

    • Author(s)
      Takayuki Tokunaga,Motohiko Tanaka,Kentaro Tanaka,Satoshi Narahara,Youko Yoshimaru,Katsuya Nagaoka,Takeshi Kawasaki,Hiroko Setoyama,Takehisa Watanabe,Masakuni Tateyama and Yutaka Sasaki
    • Organizer
      The Liver Meeting 2018 - AASLD
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Early Prediction of Sorafenib Response in Patients with Hepatocellular Carcinoma: The Possible Role of Secretory Clusterin in Acquired Sorafenib Resistance.2018

    • Author(s)
      Satoshi Narahara,Takehisa Watanabe,Katsuya Nagaoka,Nahoko Fujimoto,Kentaro Tanaka,Takayuki Tokunaga,Takeshi Kawasaki,Youko Yoshimaru,Hiroko Setoyama,Masakuni Tateyama,Hideaki Naoe,Motohiko Tanaka and Yutaka Sasaki
    • Organizer
      The Liver Meeting 2018 - AASLD
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 進行肝細胞癌に対するソラフェニブ治療と肝動注化学療法の効果解析から検討する治療戦略2018

    • Author(s)
      徳永尭之、田中基彦、佐々木裕
    • Organizer
      第104回日本消化器病学会総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] 肝細胞癌に対するソラフェニブの治療効果を早期に予測する新規血清バイオマーカーの解析2018

    • Author(s)
      楢原哲史、渡邊丈久、田中健太郎、徳永尭之、川崎剛、吉丸洋子、立山雅邦、田中基彦、佐々木裕
    • Organizer
      第54回日本肝臓学会総会
    • Related Report
      2018 Annual Research Report
  • [Book] (薬剤性消化器疾患の治療(3)肝臓)薬剤性消化器疾患の治療2020

    • Author(s)
      長岡克弥、徳永尭之、田中基彦
    • Total Pages
      8
    • Publisher
      株式会社日本メディカルセンター
    • ISBN
      9784524263318
    • Related Report
      2020 Annual Research Report
  • [Book] 最新ガイドライン準拠消化器疾患 診断・治療指針2018

    • Author(s)
      佐々木裕、木下芳一、下瀬川徹、渡辺 守
    • Total Pages
      480
    • Publisher
      中山書店
    • ISBN
      9784521746012
    • Related Report
      2018 Annual Research Report

URL: 

Published: 2018-04-23   Modified: 2023-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi